You have free access to this content

Cancer

Cover image for Vol. 118 Issue 9

1 May 2012

Volume 118, Issue 9

Pages 2335–2561

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Original Articles
    5. Errata
    1. You have free access to this content
    2. You have free access to this content
      Other methods for improved prostate cancer detection? (page 2337)

      Carrie Printz

      Version of Record online: 20 APR 2012 | DOI: 10.1002/cncr.27584

  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Original Articles
    5. Errata
    1. You have free access to this content
      Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity (pages 2338–2366)

      Christie Eheman, S. Jane Henley, Rachel Ballard-Barbash, Eric J. Jacobs, Maria J. Schymura, Anne-Michelle Noone, Liping Pan, Robert N. Anderson, Janet E. Fulton, Betsy A. Kohler, Ahmedin Jemal, Elizabeth Ward, Marcus Plescia, Lynn A. G. Ries and Brenda K. Edwards

      Version of Record online: 28 MAR 2012 | DOI: 10.1002/cncr.27514

      • original image
      • original image
      • original image

      The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate annually to provide updated information regarding cancer occurrence and trends in the United States. This year's report highlights the increased cancer risk associated with excess weight and lack of sufficient physical activity and emphasizes the importance of efforts to promote healthy weight and sufficient physical activity in reducing the cancer burden in the United States.

    2. You have free access to this content
      Innovative cancer therapies : Putting costs into context (pages 2367–2371)

      David Khayat

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26496

      • original image
      • original image

      This commentary addresses the burden and costs of cancer care, highlighting the significant impact of cancer-related premature death on the total cost of cancer care in France. Unlike previously reported data, this article examines the true cost of new targeted therapies when the impact of the extension in survival is taken into account, providing insight applicable not only in France but worldwide.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Original Articles
    5. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions : Evidence against a precursor role (pages 2372–2377)

      Fouad I. Boulos, William D. Dupont, Peggy A. Schuyler, Melinda E. Sanders, David L. Page, Faysal A. Fedda and Jean F. Simpson

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26523

      Carcinoma subsequent to columnar cell lesions may occur in either breast and tends to show a similar grade and type distribution as sporadic breast cancer. These findings argue against columnar cell lesions being a true precursor for invasive carcinoma.

    2. You have free access to this content
      A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer (pages 2378–2384)

      Stacy Moulder, Gregory Gladish, Joe Ensor, Ana Maria Gonzalez-Angulo, Massimo Cristofanilli, James L. Murray, Daniel Booser, Sharon H. Giordano, Abeena Brewster, Julia Moore, Edgardo Rivera, Gabriel N. Hortobagyi and Hai T. Tran

      Version of Record online: 17 OCT 2011 | DOI: 10.1002/cncr.26571

      • original image

      Although everolimus (RAD001) has been successfully combined with weekly paclitaxel, this study demonstrates that combination therapy with docetaxel is not feasible due to toxicity, predominately myelosuppression. These findings are likely due to drug interactions, as both docetaxel and everolimus, but not paclitaxel, are cleared through CYP3A4.

    3. You have free access to this content
      Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer (pages 2385–2393)

      Soley Bayraktar, Ana M. Gonzalez-Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem-Bertrandt, Henry M. Kuerer, Gabriel N. Hortobagyi, Aysegul A. Sahin and Funda Meric-Bernstam

      Version of Record online: 27 SEP 2011 | DOI: 10.1002/cncr.26555

      • original image

      The type of neoadjuvant systemic therapy (NST) in HER2-positive breast cancer is predictive of pathologic complete response (pCR) rate independent of disease characteristics. Although TCH (docetaxel, carboplatin, and trastuzumab) is active, trastuzumab combined with an anthracycline-based NST shows a higher pCR rate and recurrence-free survival.

    4. Genitourinary Disease
      You have free access to this content
      Molecular characterization of kidney cancer : Association of hyaluronic acid family with histological subtypes and metastasis (pages 2394–2402)

      Andrew Chi, Samir P. Shirodkar, Diogo O. Escudero, Obi O. Ekwenna, Travis J. Yates, Rajinikanth Ayyathurai, Michael Garcia-Roig, Jeffrey C. Gahan, Murugesan Manoharan, Vincent G. Bird and Vinata B. Lokeshwar

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26520

      • original image
      • original image
      • original image
      • original image

      Among the 12 hyaluronic acid (HA) family members, which include HA synthases, hyaluronidases, and HA receptors, CD44s and RHAMM mRNA levels are significantly elevated in renal cell carcinoma subtypes when compared with normal kidney and oncocytoma specimens, regardless of the tumor size. In this study CD44s, RHAMM and combined CD44s + RHAMM markers independently predict metastasis with >80% accuracy.

    5. Gynecologic Oncology
      You have free access to this content
      Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer : A 2-cohort, phase 2 study (pages 2403–2410)

      Martee L. Hensley, Sara Kravetz, Xiaoyu Jia, Alexia Iasonos, William Tew, Lauren Pereira, Paul Sabbatini, Christin Whalen, Carol A. Aghajanian, Corinne Zarwan and Suzanne Berlin

      Version of Record online: 20 SEP 2011 | DOI: 10.1002/cncr.26569

      • original image
      • original image

      Eribulin produces objective responses in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival is 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group.

    6. Hematologic Malignancies
      You have free access to this content
      Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation (pages 2411–2419)

      Min Fang, Barry Storer, Brent Wood, Boglarka Gyurkocza, Brenda M. Sandmaier and Frederick R. Appelbaum

      Version of Record online: 16 SEP 2011 | DOI: 10.1002/cncr.26539

      • original image
      • original image

      Discordant cytogenetic results and flow cytometry results occur in a subset of patients who have acute myeloid leukemia with no clear data to guide clinical action. This study demonstrates that the detection of residual disease by either method in patients pretransplantation and post-transplantation predicts early relapse and shortened survival.

    7. You have free access to this content
      Impact of residual normal metaphases in core binding factor acute myeloid leukemia (pages 2420–2423)

      Bruno C. Medeiros, Megan Othus, Min Fang, Frederick R. Appelbaum and Elihu H. Estey

      Version of Record online: 16 SEP 2011 | DOI: 10.1002/cncr.26557

      • original image

      Distinct variables affect the survival of patients with acute myeloid leukemia (AML). The presence of cells with normal metaphases may negatively affect the outcome of AML patients with a favorable-risk karyotype.

    8. Hepatobiliary Disease
      You have free access to this content
      Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer (pages 2424–2430)

      Philip A. Philip, Michelle R. Mahoney, Kyle D. Holen, Donald W. Northfelt, Henry C. Pitot, Joel Picus, Patrick J. Flynn and Charles Erlichman

      Version of Record online: 27 SEP 2011 | DOI: 10.1002/cncr.26556

      • original image

      Erlotinib plus bevacizumab has minimal activity in patients with advanced hepatocellular cancer (HCC) based on objective response and progression-free survival. The role of targeting epidermal growth factor receptor and vascular endothelial growth factor in HCC needs further evaluation in molecularly selected patients.

    9. You have free access to this content
      Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma (pages 2431–2442)

      Qing Xie, Xiangmei Chen, Fengmin Lu, Ting Zhang, Meili Hao, Yongfeng Wang, Jingmin Zhao, Malcolm A. McCrae and Hui Zhuang

      Version of Record online: 11 OCT 2011 | DOI: 10.1002/cncr.26566

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The results from this study indicate that sex-determining region Y box 6 (SOX6) is a novel target of microRNA 155 (miR-155). This microRNA enhances liver cell tumorigenesis at least in part through the novel miR-155/SOX6/p21waf1/cip1 axis, suggesting a potential target for hepatocellular carcinoma treatment.

    10. You have free access to this content
      Postchemotherapy histological analysis of major intrahepatic vessels for reversal of attachment or invasion by colorectal liver metastases (pages 2443–2453)

      Kuniya Tanaka, Takafumi Kumamoto, Kazunori Nojiri, Kazuhisa Takeda and Itaru Endo

      Version of Record online: 22 SEP 2011 | DOI: 10.1002/cncr.26563

      • original image
      • original image

      Attachment to or invasion of major intrahepatic vessels by liver metastases is difficult to reverse by otherwise effective chemotherapy.

    11. Lung Disease
      You have free access to this content
      Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer (pages 2454–2465)

      Jin-Soo Kim, Edward S. Kim, Diane Liu, J. Jack Lee, Luisa Solis, Carmen Behrens, Scott M. Lippman, Waun Ki Hong, Ignacio I. Wistuba and Ho-Young Lee

      Version of Record online: 22 SEP 2011 | DOI: 10.1002/cncr.26492

      • original image
      • original image
      • original image
      • original image
      • original image

      Overexpression of insulin receptor is associated with poor outcome in patients with nonsmall cell lung cancer, especially those with squamous cell carcinoma.

    12. You have free access to this content
      Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy : A prospective clinical study (pages 2466–2475)

      Markus Joerger, Sjaak A. Burgers, Paul Baas, Egbert F. Smit, Tjeerd J. Haitjema, Martin P. L. Bard, Valerie D. Doodeman, Paul H. M. Smits, Andrew Vincent, Alwin D. R. Huitema, Jos H. Beijnen and Jan H. M. Schellens

      Version of Record online: 28 SEP 2011 | DOI: 10.1002/cncr.26562

      • original image
      • original image

      To the authors' knowledge, this is the first prospective study in patients with advanced nonsmall cell lung cancer (NSCLC) to describe predictive germline polymorphisms not only for platinum-gemcitabine clinical activity (excision repair cross-complementation group 1 [ERCC1] and xeroderma pigmentosum group A member 10 [XPD10]), but also for toxicity (glutathione S-transferase π 1 [GSTP1], adenosine triphosphate-dependent DNA helicase Q1 [RECQ1], and cytidine deaminase [CDA]). The results indicate that nonplatinum-containing chemotherapy for carriers of the ERCC1 T allele or the XPD10 G allele should be studied prospectively.

    13. Melanoma
      You have free access to this content
      Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma (pages 2476–2485)

      Trine O. Jensen, Henrik Schmidt, Holger J. Møller, Frede Donskov, Morten Høyer, Pia Sjoegren, Ib J. Christensen and Torben Steiniche

      Version of Record online: 22 SEP 2011 | DOI: 10.1002/cncr.26511

      • original image
      • original image

      Neutrophil infiltration and CD123+ dendritic cell infiltration in primary melanoma are independently associated with poor prognosis. Melanoma cell expression of pSTAT3 is strongly associated with the surrounding immune infiltrate.

    14. Neuro-Oncology
      You have free access to this content
      A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases (pages 2486–2493)

      May Tsao, Wei Xu and Arjun Sahgal

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26515

      • original image
      • original image
      • original image
      • original image
      • original image

      We provide updated hazard ratios on overall survival, local control, and distant brain control by pooling those randomized studies comparing whole-brain radiation plus radiosurgery boost to whole-brain radiotherapy alone or radiosurgery alone. We conclude no overall survival advantage to whole-brain radiotherapy despite higher rates of local control and distant brain control when added to radiosurgery; furthermore, as additional whole-brain radiation may harm neurocognition and increase the risk of late side effects, the option of radiosurgery alone should be routinely considered for selected patients.

    15. Sarcoma
      You have free access to this content
      Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo : Procoagulant nature of osteosarcoma (pages 2494–2506)

      Jiro Ichikawa, Heather A. Cole, Robert A. Magnussen, Nicholas A. Mignemi, Matthew Butler, Ginger E. Holt, Lynda O'Rear, Masato Yuasa, Baldeep Pabla, Hirotaka Haro, Justin M. M. Cates, Heidi E. Hamm, Herbert S. Schwartz and Jonathan G. Schoenecker

      Version of Record online: 27 SEP 2011 | DOI: 10.1002/cncr.26518

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Osteosarcoma cells express cofactors and receptors of the coagulation cascade that directly and indirectly promote a malignant phenotype by increasing cell proliferation and forming a thrombus. Osteosarcoma growth can be attenuated by targeting this procoagulant activity with low molecular weight heparin.

    16. Discipline

      Clinical Trials
      You have free access to this content
      A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid (pages 2507–2515)

      Manish Sharma, Hassan Khan, Peter F. Thall, Robert Z. Orlowski, Roland L. Bassett Jr., Nina Shah, Qaiser Bashir, Simrit Parmar, Michael Wang, Jatin J. Shah, Chitra M. Hosing, Uday R. Popat, Sergio A. Giralt, Richard E. Champlin and Muzaffar H. Qazilbash

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26517

      • original image
      • original image
      • original image

      Adding bortezomib to a preparative regimen of arsenic trioxide, ascorbic acid, and high-dose melphalan is safe and well tolerated in patients with myeloma.

    17. Disparities Research
      You have free access to this content
      Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California (pages 2516–2524)

      Carol A. Parise, Katrina R. Bauer and Vincent Caggiano

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26542

      • original image
      • original image

      African American and Hispanic women in Los Angeles are less likely than white women to receive adjuvant radiation after breast-conserving surgery. In all regions of California, women older than 70 years are also less likely to receive radiation therapy after breast-conserving surgery.

    18. Medical Oncology
      You have free access to this content
      Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis (pages 2525–2531)

      George R. Simon, Michael J. Schell, Mubeena Begum, Jongphil Kim, Alberto Chiappori, Eric Haura, Scott Antonia and Gerold Bepler

      Version of Record online: 25 OCT 2011 | DOI: 10.1002/cncr.26522

      • original image

      The results from tailored first-line therapy using the molecular determinants excision repair cross complementing 1 and ribonucleotide reductase 1 indicate that personalized therapy improves survival over standard treatment-selection approaches.

    19. Pathology
      You have free access to this content
      Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes (pages 2532–2540)

      Terry Hyslop, David S. Weinberg, Stephanie Schulz, Alan Barkun and Scott A. Waldman

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26516

      • original image
      • original image
      • original image

      Clinicopathologic processes underlying established differences in survival in blacks compared with whites with lymph node-negative (pN0) colorectal cancer remain incompletely understood. This study reveals that these disparities are associated with differences in occult tumor burden quantified across the regional lymph node network, offering a molecular diagnostic paradigm to eliminate racial gaps in stage-specific mortality.

    20. Pediatric Oncology
      You have free access to this content
      A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor (pages 2541–2551)

      Arif N. Ali, Roberto Diaz, Hui-Kuo Shu, Arnold C. Paulino and Natia Esiashvili

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26554

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Adults in the Surveillance, Epidemiology and End Results (SEER) database have statistically worse overall survival than pediatric patients despite previous studies showing comparable outcome when treated on protocol. The worse outcome of SEER adults likely stems from incorrect diagnosis, inadequate staging, and undertreatment.

    21. Radiation Oncology
      You have free access to this content
      Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation (pages 2552–2559)

      Alice Ho, Peter Cordeiro, Joseph Disa, Babak Mehrara, Jean Wright, Kimberly J. Van Zee, Clifford Hudis, Amanda McLane, Joanne Chou, Zhigang Zhang, Simon Powell and Beryl McCormick

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26521

      • original image
      • original image
      • original image

      Long-term clinical outcomes and rate of permanent implant removal or replacement (PIRR) were evaluated in 151 patients treated with 2-stage tissue expander/permanent implant reconstruction, chemotherapy, and postmastectomy radiation with uniform treatment and sequencing. Favorable implant outcomes (7-year PIRR rate of 29%) and locoregional control (7-year rate of 100%) were achievable in this select population of patients.

  4. Errata

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Original Articles
    5. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
      Erratum: Early onset HER2-positive breast cancer is associated with germline TP53 mutations (page 2561)

      Version of Record online: 31 AUG 2011 | DOI: 10.1002/cncr.26534

      This article corrects:

      Early onset HER2-positive breast cancer is associated with germline TP53 mutations

      Vol. 118, Issue 4, 908–913, Version of Record online: 14 JUL 2011

    5. You have free access to this content

SEARCH

SEARCH BY CITATION